Inergetics Inc (NRTI) Gross Profit Margin starting from the second quarter 2015 to second quarter 2014, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Inergetics Inc  (NRTI)


Inergetics Inc's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NRTI Gross Profit Margin (Jun 30 2015)
Q2 		(Mar 31 2015)
Q1 		(Dec 31 2014)
Q4 		(Sep 30 2014)
Q3 		(Jun 30 2014)
Q2
Y / Y Revenue Change -61.78 %
Seq. Revenue Change -29.49 %
Revenue In Millions $0.20
Gross Profit Margin 22.93 %
Gross Profit Margin Total Ranking # 3820
Gross Profit In Millions $0.05
Y / Y Gross Profit Change -78.47 %
Seq. Gross Profit Change -


Commenting Second Quarter 2015 Gross Profit Margin
Inergetics Inc achieved Gross Profit of $0 millions compare to Gross Loss of $-0.47 millions booked in the previous quarter. Despite the sequential Revenue deterioration in Q2 of -29.49 % Inergetics Inc managed to reduce Cost of Sales and turn into profitability by achieving a Gross Profit of 0 compare to Gross Loss of $-0.47 millions realized in the previous quarter. Company accomplished Gross Profit Margin of 22.93 %, below company average.


Observing second quarter 2015 results within Major Pharmaceutical Preparations industry 122 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from to 3820.
Learn about Gross Margin
NRTI's Gross Profit Margin second quarter 2015 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 380
Overall # 3096

Gross Profit Margin Statistics
High Average Low
44.02 % 30.28 % 16.29 %
(Dec 31 2013)   (Sep 30 2014)


NRTI Gross Income Trends • More of NRTI's Profitabilty Ratios • NRTI Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
NRTI's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
NRTI's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for NRTI's Competitors
Gross Profit Margin Profit Margin for Inergetics Inc's Suppliers
Gross Profit Margin Profit Margin for NRTI's Customers

You may also want to know
NRTI's Annual Growth Rates NRTI's Profitability Ratios NRTI's Asset Turnover Ratio NRTI's Dividend Growth
NRTI's Roe NRTI's Valuation Ratios NRTI's Financial Strength Ratios NRTI's Gross Profit Growth
NRTI's Roa NRTI's Inventory Turnover Ratio NRTI's Growth Rates NRTI's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2015, within Major Pharmaceutical Preparations Industry Gross Profit MarginJun 30 2015 MRQ Gross ProfitJun 30 2015 MRQ Revenue
Insite Vision Inc  63.01 %$ 0.247  Millions$ 0.392  Millions
Aytu Biopharma Inc  62.97 %$ 0.150  Millions$ 0.238  Millions
Merck and Co Inc   61.64 %$ 6,031.000  Millions$ 9,785.000  Millions
Spero Therapeutics Inc   61.58 %$ 2.248  Millions$ 3.651  Millions
Reshape Lifesciences Inc  61.06 %$ 0.048  Millions$ 0.079  Millions
Pfenex Inc   59.78 %$ 1.369  Millions$ 2.290  Millions
Veru Inc   59.29 %$ 4.633  Millions$ 7.813  Millions
Teva Pharmaceutical Industries Limited  58.44 %$ 2,902.000  Millions$ 4,966.000  Millions
Prestige Consumer Healthcare Inc   58.42 %$ 112.236  Millions$ 192.132  Millions
Akorn Inc  58.12 %$ 128.407  Millions$ 220.920  Millions
Abbott Laboratories  57.10 %$ 2,952.000  Millions$ 5,170.000  Millions
Vivus Inc  57.06 %$ 13.115  Millions$ 22.985  Millions
Neuropathix Inc.  56.71 %$ 0.067  Millions$ 0.118  Millions
Cv Sciences Inc   56.29 %$ 1.359  Millions$ 2.414  Millions
Mallinckrodt Plc  55.28 %$ 533.500  Millions$ 965.100  Millions
Nektar Therapeutics  53.51 %$ 12.127  Millions$ 22.661  Millions
Aratana Therapeutics, Inc.  52.61 %$ 0.121  Millions$ 0.230  Millions
Avid Bioservices Inc   52.35 %$ 5.063  Millions$ 9.671  Millions
Ampio Pharmaceuticals inc   52.35 %$ 0.097  Millions$ 0.184  Millions
Panbela Therapeutics Inc   51.18 %$ 0.149  Millions$ 0.291  Millions
Propanc Biopharma Inc   50.00 %$ 0.004  Millions$ 0.008  Millions
Societal Cdmo Inc   49.65 %$ 9.265  Millions$ 18.660  Millions
China Yct International Group, Inc.  49.48 %$ 5.683  Millions$ 11.486  Millions
American Bio Medica Corporation  48.02 %$ 0.849  Millions$ 1.768  Millions
Harrow Inc   46.62 %$ 0.917  Millions$ 1.967  Millions
Prophase Labs Inc   45.96 %$ 1.007  Millions$ 2.191  Millions
Ernexa Therapeutics Inc   45.44 %$ 2.814  Millions$ 6.193  Millions
Processa Pharmaceuticals Inc   45.07 %$ 0.009  Millions$ 0.020  Millions
Chembio Diagnostics Inc   44.95 %$ 3.019  Millions$ 6.716  Millions
Elite Pharmaceuticals Inc   44.66 %$ 0.966  Millions$ 2.163  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.